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Abstract This policy commentary addresses a significant access to care issue that faces
methadonemaintenance patients seeking residential treatment in the United States. Methadone
maintenance therapy (MMT) has demonstrated strong efficacy in the outpatient treatment of
opiate dependence. However, many opiate dependent patients are also in need of more
intensive interventions, such as residential care. Many publically-funded residential treatment
programs explicitly decline to admit MMT patients, contending that methadone raises both
clinical and administrative problems in treatment. Although advocates within the field believe
that this issue is a violation of the American’s with Disabilities Act (ADA) in the United States,
no lawsuits have been brought forth, and there is no legal precedent or public policy to inform
the debate. The present paper provides an overview of this problem and discusses factors that
may contribute to the problem, including an abstinence-oriented philosophy and treatment
program operational concerns. The paper also draws parallels between methadone and other
medical conditions and analyzes the problem in the context of disabilities encompassed in the
ADA. Finally, recommendations on strategies for increasing access to residential care for
MMT patients are provided.
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Opiate dependence is a major public health concern that contributes to a range of individual
and social problems, including mortality, transmission of disease, psychopathology, and
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criminality (Teeson et al. 2006). Methadone maintenance therapy (MMT) has highly
demonstrated efficacy at reducing illicit opiate use (Gossop et al. 2003) and improving
overall psychosocial functioning, including employment, criminal activity, and contraction
of HIV/AIDS. In the United States, there are approximately 1,396 MMT programs serving
over 254,000 patients (SAHMSA 2006).
MMT patients receive limited services as part of their opioid replacement treatment,
including medical screening, dosing, and outpatient counseling. However, for many
patients, a higher level of care is necessary to deal with their opiate addiction or other
comorbid disorders. Consequently, many MMT patients seek out a higher level of care at
residential treatment programs.
For opiate-dependent patients receiving MMT, the adage “more is better” seems to be
supported by research. For example, delivery of more treatment services within the context
of methadone treatment has been found to lead to better outcomes, with those receiving a
higher number of services showing greater improvements, even after controlling for patient
factors (Gossop et al. 2003). This study found that “treatment dose,” as measured by
number of days in treatment, number of treatment sessions attended, and number of
services received, was predictive of positive outcome.
Evidence also seems to suggest that patients with previous methadone treatment may
differentially benefit from residential treatment. For example, Cheung and Ch’ien (1999)
found that patients who participated in methadone treatment prior to residential treatment
were five times more likely to be abstinent from heroin at a three year follow-up point. The
authors interpreted the findings to suggest that participation in methadone programs may
facilitate successful outcome in residential treatment and that a compatible relationship
between the harm reduction and abstinence oriented approaches to treatment may be
possible.
Despite the effectiveness and widespread use of MMT, and the demonstrated benefit
of combining MMT with other more intensive forms of treatment, integration remains
a controversial topic. In fact, many substance abuse treatment providers assert that
MMT is incompatible with recovery and the abstinence-based treatment models of most
residential treatment programs. Methadone maintenance program staff have reported
years of frustration in trying to obtain residential treatment services for their MMT
patients, as many state-licensed and publicly funded residential treatment programs have
policies in place that explicitly deny access to care for MMT patients (Zweben et al.
1999). This paper is not intended to an exhaustive critique of access to care issues for
MMT patients, but proposes to focus on several key factors that may contribute to access
to care problems in the United States, offer several arguments in favor of increasing access
to care, and provide some practical recommendations for increasing access to care for this
population.
Contributing Factors
Multiple factors likely contribute to the current status of residential treatment for MMT
patients in the United States. Although systems level factors such as the limited availability
of residential treatment and insurance/payment issues probably play an important role, this
section will focus on the impact of two key factors, including the impact of the abstinence-
oriented philosophy that is commonly espoused with residential treatment programs and the
operational concerns that face residential treatment programs who extend treatment services
to MMT patients.
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Impact of Abstinence-Oriented Philosophy
Until the last several decades, the evolution of substance abuse treatment occurred largely
in isolation from scientific study or traditional medical care (Miller et al. 2006). Mainstream
society and the medical field viewed addictions as moral problems of the will, rather than
valid medical disorders, and consequently devoted few resources to scientifically
investigate effective treatments. As a result, substance abuse treatment emerged largely in
the form of treatment by compassionate peers, who were themselves in recovery. This peer-
led perspective has generally been strongly influenced by viewpoints that complete
abstinence is the only route to recovery and that many medications, including methadone,
merely enable individuals to maintain addictive lifestyles. This viewpoint is also widely
held in society at large, in which abstinence models tend to evoke more support than
methadone. Zweben and Sorensen (1988) pointed out that American society regards
methadone as a “necessary evil” and believe that “patients should use the least possible
amount,” an adage that is unsupported by research. With the rise of behavioral research in
the last several decades, we now have a variety of empirically evaluated treatment
approaches that do not follow an abstinence-oriented philosophy. Yet abstinence models of
recovery, still have a dominant influence, especially in residential treatment facilities.
The use of abstinence-oriented models, such as Alcoholics Anonymous, has been found
to benefit patients who electively choose to participate in such programs, but not those who
are coerced to participate (Kownacki and Shadish 1999). Despite this, abstinence-oriented
treatment philosophies have become integrated into a variety of other treatment modalities,
including many residential treatment programs.
Providers who hold an abstinence-based view of recovery have been found to be less
receptive to the dissemination of evidence-based practices and to rely more heavily on
testimonial evidence and personal experience when making clinical decisions (Miller et al.
2006). These tendencies may have contributed to the bias against MMT that often exists
within residential treatment programs. Decades of misinformation within these abstinence-
oriented programs and lack of receptivity to evidence demonstrating effectiveness have
created a stigma against the use of methadone in recovery. This stigma, in turn, has resulted
in the denial of treatment services to MMT within many residential treatment programs.
Treatment Program Operational Concerns
Residential treatment programs often have treatment philosophies contending that abstinence
from all substances is necessary for “true” recovery, and these beliefs about the correct path to
recovery are commonly cited as the reason for denying treatment to MMT patients. However,
Zweben et al. (1999) also describe some practical operational concerns that may serve to
prevent equal access to care. As they describe, “residential programs vary widely in their
sophistication, and some have little or no experience in dealing with medication and related
matters” (Zweben et al. 1999, pp.250). Consequently, these programs may feel unable to
adequately address issues such as safe storage, monitoring patient dosage, and collaborating
with physicians and methadone programs.
While much of the stigma against the use MMT does not seem grounded in evidence,
some important arguments against the integration of MMT and residential treatment have
been put forth. Residential treatment programs are faced with a complex context for their
clinical decision making (Zemore and Kaskutas 2008). Unlike methadone clinics, in which
the behavior of one client has little effect on others, patients within residential treatment
programs are highly dependent on one another. Here the behavior of one individual can
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have a huge effect on the overall environment and, consequently, what may be beneficial to
one client may be harmful to the community as a whole.
Some residential treatment providers argue that the many frequent trips to the methadone
clinic that are often required for appropriate dosing can significantly interfere with the
residential treatment process. For one, providing transportation to and from methadone
clinics can be timely, expensive, or impractical for residential staff. In addition, an important
component of residential treatment programs is that they are designed to help patients sever
ties to negative influences in their outside environment. Frequent trips to the methadone clinic
have been argued to provide patients with many potentially dangerous opportunities to
maintain these bonds. MMT clients who have to leave the site to get dosed may also miss
important group activities, interfering with assimilation into the community, and sometimes
making non-MMT clients feel that they receiving special privileges. The “nodding out”
behavior, or abruptly falling asleep during sedentary activity, that is sometimes associated
with methadone treatment has also been cited as potentially disruptive to groups. One last
potential complication of integrating the two forms of treatment is the ability of residential
programs to securely store and distribute take-home doses of methadone.
Arguments in Support of Increasing Access to Care
While research has demonstrated that residential treatment improves the treatment
prognosis of MMT patients, there are several other compelling reasons to increase access
to care for this population. Drawing parallels between MMT patients and patients with
other medical conditions may help to alleviate potential bias against this group by adding
historical perspective to the debate. In addition, denial of treatment may be a violation of
the Americans with Disabilities Act, which is aimed at providing equal opportunities for
individuals with physical and mental disabilities, including substance use disorders.
Parallels to Other Conditions
Although the participation of MMT patients in residential treatment raises some potential
concerns, the obstacles are not unlike what one might expect for an individual with another
medical condition, such as epilepsy (Grunfeld and Komlodi 2006). Here too, the individual
would require frequent trips to a health care provider and possibly be prescribed anti-
convulsants with side effects of drowsiness. In addition, little controversy can be found
within the literature regarding the appropriateness of residential treatment for individuals
with other medical disorders, suggesting that stigma and differences in treatment philosophy
are a driving force of denial of treatment services to MMT patients. Greenberg et al. (2007)
point out that there was similar ideological contention years ago, when psychiatric
medications were first being utilized in addiction treatment centers, but now psychiatric
medications are seen as the standard of care for patients with co-occurring disorders. In
addition, at least two published articles have demonstrated that the potential barriers to
integration of MMT and residential treatment can be successfully overcome with appropriate
staff training and collaboration between sites (Zweben et al. 1999; Sorensen et al. 2009).
Americans with Disabilities Act Implications
Limitations in access to care for MMT patients hinder these patients from obtaining needed
substance abuse and mental health treatment services. While differences in norms regarding
Int J Ment Health Addiction (2009) 7:468–474 471
effective treatments and practical considerations may serve as barriers, collaboration
between residential treatment and methadone programs would ultimately increase access to
evidence-based care for MMT patients.
Issues of disability have special salience for MMT patients (Benoit et al. 2004) who are
commonly denied services as a result of their use of prescribed medications for the
treatment of their substance dependence. In fact, many interpret the denial of residential
treatment services as a violation of the Americans with Disabilities Act (ADA; Zweben et
al. 1999). However, the ADA can be interpreted to inform the denial of treatment services
to MMT patients in several ways.
The ADA (1990) is an American civil rights law that prevents discrimination based on
disability. The law was enacted in 1990 as protects individuals with disability from
discrimination in areas such as employment and receipt of public services. The ADA
defines disability as “a physical or mental impairment that substantially limits one or more
of the major life activities of such individual.” Under this definition, an individual with
substance dependence is considered a qualified individual with a disability. One caveat to
this definition is that a qualified individual with a disability shall not include individuals
who are engaging in the illegal use of drugs. However, the definition of illegal use of drugs
does not include the use of drugs taken under the supervision of a licensed health care
professional, as is the case with prescribed methadone. Section 302 of the ADA prohibits
discrimination by health care providers in the form of denial of participation in services.
Here the imposition or application of eligibility criteria that screen out individuals with a
disability is considered discrimination. This section can be interpreted as clearly prohibiting
the denial of residential treatment services to opiate dependent MMT. However, the ADA also
specifies that denial of services on the basis of disability is not considered discrimination in
the case that making such accommodations would fundamentally alter the nature of the
service or would result in an undue burden. This section can be interpreted to exempt denial
of treatment to MMT patients from the label of discrimination, by arguing that allowing
MMT to participate in abstinence based treatment would fundamentally alter the nature of the
treatment program and compromise the recovery of other treatment participants.
While discrimination against individuals taking prescribed medications through the
denial of treatment may be a violation of the ADA, the authors are aware of no litigation
that has yet been brought forth to establish legal precedence with regard to methadone
within residential treatment. In addition, as yet there are no legislative policies or licensing
regulations in place that address equal access to care for MMT patients.
Discussion and Recommendations
It was the purpose of the present paper to increase awareness of this access-to-care issue,
explain both sides of the argument, and provide a rationale for improving access to care for
MMT patients. It should be acknowledged however, that this paper is far from a
comprehensive evaluation of access to care issues that face MMT patients. The paper
focuses on several important factors that may contribute to the present access to care
inequities and offers several arguments in favor of increasing access to care. The paper is
also limited to examples from the United States and research and discussion would be
further enhanced by examining additional perspectives.
In the paper, we aimed to demonstrate that access to residential treatment would clearly
benefit MMT patients. While no legal precedence has been established regarding the
implications of MMT patients’ access to care, a solution in which MMT patients can
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receive residential treatment without fundamentally altering the treatment experience of
other patients would be optimal. Greenberg et al. (2007) suggest several practical strategies
that may improve the feasibility of methadone within residential treatment, including
educating staff about methadone to eliminate misconceptions and reduce staff generated
stigma. In addition, the authors recommend preparing staff to deal with difficult situations
regarding methadone, including jealousy from other patients and nodding off behaviors.
The authors also recommend educating other patients on methadone related topics and
facilitating twelve-step oriented MMT groups within the program.
A remaining issue is whether the treatment models used in medically-oriented
methadone programs and abstinence-oriented therapeutic communities are so incompatible
that they cannot be combined effectively. Cherry (2008) points out that philosophical
differences can so deeply divide mental health and addiction services that it is impractical to
integrate them. While further research is needed on this topic, Sorensen et al. (2009)
recently completed a trial that found similar outcomes of residential treatment for matched
MMT and non-MMT patients. In the trial, MMT patients were found to have residential
treatment and substance abuse outcomes that were no different than their non-MMT
counterparts, painting an optimistic picture of the possibility of equal access to residential
care for MMT patients.
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